Pharmaids Pharmaceuticals FY2025-26: Loss Narrows Amid CRDMO Transition

Consolidated Revenue: Rs 2,817.12 Lakh | Net Loss: Rs 1,157.19 Lakh

Reader Takeaway: Revenue growth is positive, but achieving profitability remains key as the company transitions to a CRDMO model.

What just happened

Pharmaids Pharmaceuticals Limited has released its 37th Annual Report for the fiscal year 2025-26, highlighting key financial and strategic developments. The company reported a consolidated revenue of Rs 2,788.24 lakh (approximately Rs 27.88 crore), a significant increase from Rs 1,944.74 lakh in the prior fiscal year. Despite revenue growth, the company posted a consolidated net loss of Rs 1,157.19 lakh (approximately Rs 11.57 crore), which is a slight improvement from the net loss of Rs 1,350.51 lakh in FY 2024-25. Basic and diluted Earnings Per Share (EPS) stood at a loss of Rs 3.31 for FY26 compared to a loss of Rs 3.05 in FY25.

On a standalone basis, Pharmaids Pharmaceuticals saw a substantial jump in revenue to Rs 1,060.25 lakh (Rs 10.60 crore) in FY 2025-26, up from Rs 234.09 lakh in FY 2024-25.

Why this matters

The results indicate revenue momentum for Pharmaids Pharmaceuticals as it pursues a strategic transformation. Shareholders will be keen to see if the company can leverage its growing top line to eventually achieve profitability. The transition to a global Contract Research, Development, and Manufacturing Organization (CRDMO) is a significant strategic pivot, and these results provide an early look at the financial implications.

The backstory

Pharmaids Pharmaceuticals is undergoing a business transition, aiming to evolve into a comprehensive CRDMO. This involves offering end-to-end services in the contract research and manufacturing space. The company has been making strategic moves, including leadership changes and operational adjustments, to support this long-term growth vision. Recent years have seen efforts to build infrastructure and onboard new talent.

What changes now

The company has completed strategic divestments, including the sale of its step-down subsidiary, Siri Labvivo Diet Private Limited, and exited its partnership in Anugraha Chemicals for Rs 10.24 crore. It also monetized land parcels for Rs 19.36 crore. A subsidiary, Adita Bio Sys Private Limited, received A2LA accreditation for medical device testing. Leadership changes include the appointment of Mr. Pattamadai Natarajasarma Vijay as Chairman and Dr. Yogananda Moolemath as an Independent Director.

Risks to watch

Key risks include the company's continued unprofitability on a consolidated basis and the execution risk associated with its ambitious transition to a global CRDMO. Realizing returns from new infrastructure and business development efforts will be crucial. Dependence on related party transactions for asset sales could also be a point of scrutiny.

Peer comparison

Information on comparable companies in the Indian CRDMO space and their recent financial performance would provide better context. Generally, the CRDMO sector is competitive, with companies focusing on R&D capabilities, regulatory compliance, and manufacturing scale.

Context metrics (time-bound)

• FY 2025-26 Consolidated Revenue: Rs 2,788.24 lakh (up from Rs 1,944.74 lakh in FY 2024-25).
• FY 2025-26 Consolidated Net Loss: Rs 1,157.19 lakh (down from Rs 1,350.51 lakh in FY 2024-25).
• Land Sale Consideration: Rs 19.36 crore (September 06, 2025).
• Anugraha Chemicals Exit: Rs 10.24 crore (effective March 27, 2026).

What to track next

Investors should closely monitor Pharmaids Pharmaceuticals' progress in converting its increased revenue into profitability. The success of its CRDMO business model, expansion of its service offerings, and further strategic capital allocation decisions will be key indicators.